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Abstract: MicroRNAs are small non-coding RNAs that regulate gene expression at the transcriptional or posttranscrip-
tional level. They are involved in cellular development, differentiation, proliferation and apoptosis and play a significant 
role in cancer. Examination of tumor-specific microRNA expression profiles has revealed widespread deregulation of 
these molecules in diverse cancers. Several studies have shown that microRNAs function either as tumor suppressor genes 
or oncogenes, whose loss or overexpression respectively has diagnostic and prognostic significance. It seems that mi-
croRNAs act as major regulators of gene expression. In this review, we discuss microRNAs’ role in cancer and how mi-
croRNAs exert their functions through regulation of their gene targets. Bioinformatic analysis of putative miRNA binding 
sites has indicated several novel potential gene targets involved in apoptosis, angiogenesis and metastatic mechanisms. 
Matching computational prediction analysis together with microarray data seems the best method for microRNA gene tar-
get identification. MicroRNAs together with transcription factors generate a complex combinatorial code regulating gene 
expression. Thus, manipulation of microRNA-transcription factor gene networks may be provides a novel approach for 
developing cancer therapies.  
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1. INTRODUCTION 
  We are in the beginning of a new era in cancer research 
that started with the identification of a novel category of 
genes, the microRNAs. They consist a new class of non-
protein-coding small RNAs, which regulate the expression of 
more than 30% of protein-coding genes at the post transcrip-
tional and translational level [1]. Each one can control hun-
dreds of gene targets by translational repression, mRNA 
cleavage, and mRNA decay initiated by miRNA-guided 
rapid deadenylation [1, 2]. They regulate cell proliferation 
and apoptosis and function as oncogenes or tumor suppres-
sors [3, 4]. It is important to mention that so far they were 
considered to be negative regulators but recent studies 
showed that can also have positive effect in gene expression 
[5]. More than 50% of microRNA genes are located in can-
cer-associated genomic regions or in fragile sites, suggesting 
that miRNAs may play a more important role in the patho-
genesis of a limited range of human cancers than previously 
thought [6].  
  The major steps for cancer development include initia-
tion, promotion, malignant conversion, progression, and me-
tastasis [7]. Many factors influence the development of can-
cers through inhibition or promotion of tumor development. 
Actually there is a combined interaction of both tumor sup-
pressors and cancer inducers genes, the so-called oncogenes. 
The unique expression profiles of different microRNAs in 
different types of cancers and at different stages in one can-
cer type suggest that microRNAs can function as novel bio- 
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markers for disease diagnostics and may present a new strat-
egy for microRNA gene therapy [8]. Interestingly, more and 
more evidence indicates that microRNAs also play an impor-
tant role in many human diseases, ranging widely from can-
cers, to heart disease, infections as HIV to metabolic dis-
eases [3, 9-11]. This evidence includes, but not limited to, 
(1) a unique set of miRNAs exists in a specific disease; (2) a 
unique expression of miRNAs in a certain human disease 
and (3) aberrant expression of miRNAs in human disease. 
2. MicroRNA BIOGENESIS 
  Regarding the history of these novel genes we can briefly 
mention that the important function of microRNAs was not 
known until microRNA (let-7) was identified in a variety of 
organisms such as C. elegans, Drosophila melanogaster and 
most importantly in humans [12-15]. Since that time, 
miRNA-related research has become one of the most chal-
lenging fields in biomedical science. The first micro RNA 
(lin-4) was found in 1993 [16] and since then more than 700 
microRNAs have been identified and being added in mi-
croRNA databases. In order to understand the action of mi-
croRNAs we need to know how they are produced. The main 
characteristic is that they are single-stranded RNAs consist-
ing of 20 to 25 nucleotides. MicroRNAs originate from 
genes that are called miRNA genes. Specifically, in the nu-
cleus large RNA precursors (whom length vary from several 
tenths to more than 1000 nucleotides) are named primary 
microRNAs (pri-miRNAs) and transcribed by RNA polym-
erase II (Pol II) as well as Pol III with 5’ cap and 3’ poly A 
tails. These pri-miRNAs are recognized by a microprocessor 
complex which is composed of the nuclear RNase III Drosha 
together with its double-stranded RNA binding domain   
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(dsRBD) partner DiGeorge syndrome critical region 8 
(DGCR8). The pri-miRNAs are cut into the miRNA precur-
sors (pre-miRNAs) with an approximately 70 nucleotide 
stem-loop structure [17]. The pre-miRNAs with 2
nd hairpin 
structure are then transported into cytoplasm by the trans-
porter Exportin 5, and this process is RanGTP dependent 
[18]. In the cytoplasm, the pre-miRNAs were further proc-
essed into the 19–24 nucleotide double-stranded miRNA 
miRNA* complex by another RNase III enzyme, called 
Dicer, together with its dsRBD partner TRBP [18, 19]. Then, 
the mature miRNA sequences enter the RNA-induced si-
lence complex (RISC) and target specific gene expression 
awhile the opposite strand miRNA* sequences are degraded 
by unknown mechanism. 
3. THE ROLE OF MicroRNAs IN HUMAN DISEASES 
  Several studies showed that miRNAs have a fundamental 
role in a great spectrum of diseases such as cardiovascular, 
rheumatologic, infectious, inflammatory, autoimmune and 
metabolic diseases. Poy et al. (2004) showed that overex-
pression of miR-375 inhibited glucose-induced insulin secre-
tion. In conversion, down-regulated miR-375 promoted insu-
lin secretion [20]. It is well known that diabetes is related to 
insulin resistance. This suggests that miR-375 is a regulator 
of insulin secretion and may become a novel pharmacologi-
cal target for the treatment of diabetes. Esau and colleagues 
(2006) studied the effect of miR-122 in lipid metabolism and 
observed the decrease in plasma cholesterol level and a sig-
nificant improvement in liver steatosis by inhibiting miR-
122 expression [21]. This was also observed by Krutzfeldt 
and colleagues [22]. Specifically, a new class of miRNA 
inhibitors which are known as antagomirs were used to 
knockdown the miR-122 expression. It was found that down-
regulation of miR-122 significantly decreases the plasma 
cholesterol levels after four days of treatment. This suggests 
that miR-122 is a key regulator of cholesterol and fatty acid 
metabolism in the adult liver and a promising therapeutic 
target for metabolic disease.  
  Many miRNAs have also identified in several viruses, 
like HIV, HBV, HCV, Epstein Barr virus (EBV) and human 
cytomegalovirus (HCMV) [23-27]. Surprisingly, viruses are 
involved in miRNA production but the exact mechanism for 
virus-encoded miRNA biogenesis is still unclear. One impor-
tant function of miRNAs is to control viral replication when 
the virus infects a cell and in that way to further control virus 
infection. A liver-specific miRNA, the miR-122 (which was 
mentioned previously) modulates HCV RNA abundance and 
HCV replication [28]. In that study it was noticed a signifi-
cant loss (about 80%) of autonomously replicating hepatitis 
C viral RNAs by knocking down miR-122.  
  Regarding the effect of microRNAs in neurologic dis-
eases, they regulate brain and neuron development [29] aber-
rant expressions of these miRNAs are associated with sev-
eral neuronal diseases, including Tourette’s syndrome [30], 
Alzheimer’s disease [31], schizophrenia and schizoaffective 
disorder [32].  
  As concerns the cardiovascular diseases, miRNAs play 
an important role in cardiac development and contractility. It 
is found that several heart diseases are associated with the 
aberrant expression of certain miRNAs. For example, car-
diac-specific inhibition of miR-1 expression in infarcted rat 
hearts relieved arrhythmogenesis [33]. These suggest that 
miR-1 may have an important pathophysiological function in 
heart failure and may serve as a potential antiarrhythmic 
target for gene therapy. Furthermore, recent studies showed 
that another miRNA, miR-133, was associated with cardiac 
hypertrophy [34]. Overexpression of miR-133 inhibits hy-
pertrophic symptom in both neonatal and adult mouse myo-
cytes whereas, down regulation of miR-133 enhances hyper-
trophic growth in mouse heart [34]. This suggests that miR-
133 is involved to the pathogenesis of heart hypertrophy and 
over expression of miR-133 in a hypertrophic heart may 
serve as a novel gene therapy for preventing pathological 
cardiac hypertrophy. 
4. MicroRNAs IN CANCER 
  Cancer is the first leading cause of death after cardiovas-
cular diseases. It has been shown that microRNAs are in-
volved in carcinogenesis development. In order to identify 
the exact role of microRNAs in cancer pathogenesis, specific 
microRNAs were overexpressed or knocked down and the 
initiation and development of different types of malignancies 
were observed. Recognition of miRNAs that are differen-
tially expressed between tumor tissues and normal tissues 
may help to identify those miRNAs that are involved in hu-
man cancers and further establish the apparent pathogenic 
role of miRNAs in cancers [35]. When cells exhibit abnor-
mal growth and loss of apoptosis function, it usually results 
in cancer formation. Cheng et al. showed that microRNAs 
regulate mechanisms such as cell growth and apoptosis [36]. 
Most of them are related to different types. For example let-7 
may control lung cancer development, or at least play a criti-
cal role in the pathogenesis of lung cancer. Takamizawa   
et al. observed that the expression levels of let-7 were fre-
quently reduced in both in vitro and in vivo lung cancer stud-
ies; reduced let-7 expression was significantly associated 
with shortened postoperative survival, independent  of dis-
ease stage [15]. Regarding breast cancer, Iorio et al. found 
that the miRNA expression patterns were significantly dif-
ferent between normal and neoplastic breast tissues; miR-
125b, miR-145, miR-21, and miR-155 were significantly 
reduced in breast cancer tissues [35]. They also observed that 
the expression of miRNAs was correlated with specific 
breast cancer biopathologic features, such as tumor stage, 
proliferation index, estrogen and progesterone receptor ex-
pression, and vascular invasion. Colorectal neoplasia (colon 
cancer) is also associated with alteration in miRNA expres-
sion. Michael et al. identified 28 different miRNAs in colo-
nic adenocarcinoma and normal mucosa, and found that the 
expression of two mature miRNAs, miR-143, and miR-145, 
was consistently reduced at the adenomatous and cancer 
stages of colorectal neoplasia [37]. Many factors influence 
the development of cancers: some inhibit tumor development 
(tumor suppressors), while others promote cancer develop-
ment (cancer inducers). The formation of cancer is the com-
bined interaction of both tumor suppressors and cancer in-
ducers. Several experiments suggest that microRNAs may 
function as a novel class of oncogenes and tumor suppressor 
genes [38]. Those miRNAs whose expression is increased in 
tumors may be considered as oncogenes. These oncogene 
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opment by negatively inhibiting tumor suppressor genes 
and/or genes that control cell differentiation or apoptosis. As 
opposed to oncomirs, some miRNAs expression is decreased 
in cancerous cells. These types of miRNAs are considered 
tumor suppressor genes. Tumor suppressor miRNAs usually 
prevent tumor development by negatively inhibiting onco-
genes and/or genes that control cell differentiation or apopto-
sis. miRNA let-7 is one of the founding members of the 
miRNA family and highly conserved [39]. The highest levels 
of let-7 expression occur in differentiated adult tissues [40]. 
Inappropriate expression of let-7 results in oncogenic loss of 
differentiation. In humans, let-7 is located at a chromosome 
region that is usually deleted in human cancers [6]. 
5. MicroRNAs CANCER SIGNATURES HAVE DIAG-
NOSTIC AND PROGNOSTIC SIGNIFICANCE 
  The development of microRNA microarrays have been 
useful in analyzing the microRNAome in hundreds of clini-
cal samples [41]. Comparison of microRNA expression lev-
els between normal and tumor derived from fresh-frozen or 
paraffin-embedded tissue samples revealed the microRNAs 
involved in carcinogenesis. Tumors originated from various 
tissues can be classified solely on the basis of microRNA 
expression profiles. The first pilot study performed by Lu  
et al. revealed that 129 microRNAs were able to classify 
human cancers [42]. Specifically these microRNAs were 
found down-regulated in cancer relative to normal tissues, 
suggesting a suppression of microRNA expression during 
carcinogenesis. In addition, microRNA profiles were infor-
mative reflecting the developmental lineage and differentia-
tion state of tumors. Therefore, in a global sense, miRNAs 
might function to drive cells into a more differentiated state, 
and the expression profiles of miRNAs in tumors compared 
with normal tissues might represent the degree of differentia-
tion in those cells.  
  The advantage of microRNAs relative to mRNA gene 
signatures is shown by the ability of microRNAs to classify 
poorly differentiated cancers while mRNA gene signatures 
failed to classify them. A very recent study by Rosenfeld et al. 
suggested that microRNAs can accurately identify cancer 
tissue origin [43]. This is of great clinical importance because 
microRNAs may be used identifying the tissue in which can-
cers of unknown primary origin arose. In this study using 
microRNA microarray data from 253 samples, they were 
able to classify 22 different cancer types using a 48 miRNA 
classifier with accuracy >90%. All these findings reveal the 
potential of microRNA profiling in cancer diagnosis.  
  Furthermore, microRNAs except distinguishing normal 
and cancers have been correlated with survival in cancer 
patients. Recently Yanaihara et al. identified statistical 
unique profiles, which could discriminate lung cancers from 
noncancerous lung tissues as well as molecular signatures 
that differ in tumor histology [44]. MicroRNA expression 
profiles correlated with survival of lung adenocarcinomas, 
including those classified as disease stage I. High miR-155 
and low let-7a expression correlated with poor survival by 
univariate analysis as well as multivariate analysis for hsa-
mir-155. Another study from the same group revealed that 
high expression of miR-21 is associated with poor survival 
and poor therapeutical outcome in colon adenocarcinomas 
[45]. Recently Bloomston M et al. showed that microRNA 
expression patterns were able to differentiate pancreatic ade-
nocarcinomas from normal pancreas and chronic pancreatitis 
[46]. miRNA expression profiles can also be used to distin-
guish two subtypes of diffuse large B cell lymphoma 
(DLBCL): germinal center B cell-like (GCB) and activated 
B cell-like (ABC) DLBCL, in which miR-21, miR-155 and 
miR-221 were more highly expressed in ABC-type than 
GCB-type DLBCL [47]. Those suggest that miRNA expres-
sion profile is a feasible novel biomarker for early detection 
of cancers, particularly for poorly understand tumors. 
6. MicroRNA’s GENE TARGETS 
  Above we described how microRNAs can be used as 
prognostic or diagnostic markers in cancer and predict thera-
peutic outcome. However in order to understand in greater 
detail microRNAs role in carcinogenesis we should delineate 
their mechanism of action. microRNAs exert their functions 
through binding in the 3’ UTR of genes and regulation of 
their expression. MicroRNAs can bind with perfect or imper-
fect complementarity to each strand of the double stranded 
RNA and depending on that, regulate gene expression. There 
are three major known mechanisms for miRNA-mediated 
gene regulation: translation repression, direct mRNA degra-
dation and miRNA-mediated mRNA decay [2]. Which mech- 
anism controls gene expression is entirely dependent on the 
degree of miRNA complementarity to their targeted mRNAs. 
miRNAs bind, in most cases, with imperfect complementar-
ity to their targeted mRNAs and guide mRNA translation 
repression. However, there are also several miRNAs which 
directly degrade their targeted mRNAs. The exact mecha-
nism for miRNA-mediated translation repression is still un-
known but most likely miRNA-RISC complex inhibit the 
initiation and/or elongation of protein translation by interact-
ing with a various translation factors [48]. Furthermore, it is 
shown that miRNAs mediate gene expression by guiding 
mRNA decay through deadenylation and de-capping process 
of targeted mRNAs [49], which is completely different from 
normal translation repression and/or direct mRNA degrada-
tion. It is well known that the 3’ poly(A) tail and 5’ cap are 
very important for mRNA stability and avoiding mRNA de-
cay. When miRNAs guide the removal of the 3’ poly(A) tail 
and 5’ cap of the targeted mRNAs, these targeted mRNAs 
will be degraded by cellular enzymes. In a majority of cases, 
miRNAs bind to their targeted mRNAs at the 3’ UTR with 
multiple sites. However, miRNAs targeted to the 5’ UTR 
and/or the open reading frame (ORF) can also repress gene 
expression [50]. miRNAs interact with their targeted mRNAs 
primary through the six to eight nucleotides at the 5’end of 
miRNAs, which is perfectly bound to the targeted mRNAs. 
This region is called ‘seed’ sequence in miRNAs and is high 
conserved in a same miRNA family from species to species 
[51].  
  The majority (61%) of miRNA genes are located at an 
intronic region of protein-coding genes; however can also be 
in regions of exons or intergenes. Interestingly, more than 
50% of miRNA genes can be found in cancer- associated 
genomic regions or in fragile sites, suggesting that miRNAs 
play an important role in the pathogenesis of neoplasias [6]. 
They are also located in minimal regions of heterozygosity 
loss, minimal regions of amplification, or common break-
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7. BIOINFORMATIC TOOLS FOR MicroRNA TAR-
GET IDENTIFICATION 
  In the last few years several bioinformatic tools have 
been developed to predict microRNA gene targets. These 
programs rely on a combination of specific-base pairing 
rules and conservational analysis to score possible 3-UTR 
recognition sites and enumerate putative gene targets. Pre-
dictions based solely on base-pairing rules have as a result a 
large number of false-positive hits. The number of false-
positive hits, as estimated by random shuffling of miRNA 
sequences, can be greatly reduced however by limiting hits 
to only those conserved in other organisms [52]. Important 
parameters to increase the validity of microRNA gene targets 
are the following: 1) share a high level of sequence compli-
mentarity with positions 2–8 (called seed sequence) of the 5 
side of the miRNA. 2) share a low level of sequence com-
plimentarity in the 5 side of the miRNA in addition to a high 
degree of similarity in the 3 side [53]. It is thought that a 
minimum 4 nucleotides on the 5 side must match perfectly 
and that G:U wobble pairs, despite their energetic stability, 
serve to disrupt miRNA targeting [54].  
  Increasing experimental information regarding microR-
NAs’ gene targets and signaling pathways has helped to im-
prove substantially the microRNA gene target prediction 
algorithms. Three of these algorithms are been used exten-
sively by most researchers. These are PicTar [55], Target-
ScanS [56], and miRanda [52]. PicTar is based on perfect 
seed binding of 7 nucleotides in the 5 end starting at either 
the first or second position. The free energy of miRNA:target 
binding is then computed for seeds with imperfect matches. 
To delineate a list of predicted target sites, energy thresholds 
are imposed and then a maximum likelihood score is com-
puted based on conservation across multiple organisms. Tar-
getScanS computes seed binding sites based on perfect com-
plementarity of a 7 nucleotide region conserved across five 
organisms (human, chimpanzee, dog, mouse and chicken) 
between bases 2–8 on the 5 end of the miRNA, while 
miRanda uses a modified approach to find miRNA binding 
sites which do not require perfect seed binding. Kiriakidou  
et al. also used a similar approach named “DIANA-microT” 
to predict miRNA-recognition elements, but used modified 
initial base-pairing rules that focus on the sizes of allowable 
bulges in initial seeds [57]. While conservation has been a 
primary aspect used to filter hits in most target prediction 
algorithms, it is important to realize that not all target sites 
are necessarily conserved. Programs such as the newly de-
veloped microTar, which relies on base pairing rules and 
binding free energy calculations, have moved away from 
reliance on conservation [58].  
  As the available bioinformatic algorithms predict hun-
dreds of microRNA-gene target pairs, it is evident that ex-
perimental data are needed for verification of these pairs. 
However, as it is known that several microRNAs target gene 
expression only at the protein and not at the mRNA level, the 
integration of microRNA along with protein data sets could 
be considered more effective for microRNA-gene target veri-
fication. Recently Huang et al. used microRNA with cDNA 
expression profiling data to identify human microRNA tar-
gets using Bayesian data analysis algorithm [59]. Specifi-
cally they identifed a network of 1,597 high-confidence tar-
get predictions for 104 human miRNAs, which was sup-
ported by RNA expression data across 88 tissues and cell 
types, sequence complementarity and comparative genomics 
data. The current most commonly used approach for experi-
mentally validating miRNA targets is to use a luciferase re-
porter construct by cloning the predicted binding site se-
quence of the miRNA into the 3-UTR region [60]. However, 
this approach is not high-throughput and the miRNA binding 
sequence is taken out of the context of the target transcript. 
Because miRNAs can block translation by either direct bind-
ing at the 3-UTR or degrading target mRNAs, conventional 
microarray based approaches only identify portions of the 
miRNA targets [61].  
8. MicroRNA GENE NETWORKS 
  Transcription factors (TFs) are important components of 
gene regulatory networks. Like TFs, miRNAs are trans-
acting factors that interact with many cis-regulatory ele-
ments. Therefore it is not surprising that they generate a 
complex combinatorial code [62]. Moreover, as transcription 
factors and genes containing binding sites for other transcrip-
tion factors have a high probability of being targeted by 
miRNAs. This interplay between microRNAs and transcrip-
tion factors renders miRNAs key components of gene regu-
latory networks.  
  MicroRNAs have several common features with tran-
scription factors. Specifically individual microRNAs and 
TFs can regulate dozens or hundreds of genes. Furthermore, 
genes are regulated not by a single, but by a combination of 
trans-acting factors. Many TFs bind cooperatively to their 
cognate DNA sequences and recruit other cofactors. Binding 
site accessibility provides an additional layer of gene regula-
tory control. In vivo occupancy of TF binding sites depends 
on nucleosome coverage of the site, with nucleosome posi-
tioning and remodeling being regulated processes [63]. Simi-
larly, the accessibility of a miRNA recognition site is con-
trolled by RNA binding proteins [64]. Because TFs are sub-
ject to miRNA regulation and miRNA cell type specificity, it 
is not a surprise that miRNAs and TFs are linked to one an-
other in gene regulatory networks.  
  On the other hand microRNA and TF mechanisms of 
action have several differences. For transcription to be re-
pressed, a sophisticated machinery needs to be set in place in 
a subcellular compartment (the nucleus) that is distinct from 
the production site of the protein product, the cytoplasm. The 
stability of already transcribed mRNA species sets another 
limit to the speed with which transcriptional repression can 
wipe out the expression of a target gene. In contrast, miR-
NAs can rapidly turn off protein production right at the site 
of protein production, the ribosome [65]. Furthermore 
miRNA-mediated control of gene expression is faster due to 
their small size and noncoding nature. MiRNAs may be pro-
duced more rapidly than TFs, thereby decreasing response 
times to stimuli that induce gene repression. Also, a miRNA-
repressed target can also be reactivated more rapidly than a 
transcriptionally repressed target, because such reactivation 
may involve the translocation of an already present mRNA 
to an active ribosome. 
  Only a few studies have experimentally explored miRNA 
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tor (F) could repress the transcription of a target gene (T) and 
simultaneously activate the transcription of a miRNA (M) 
that inhibits target gene translation Fig. (1). In type I circuits, 
the transcription rates of both microRNA and target gene are 
positively or negatively co-regulated by up-stream regulator 
Fig. (1a). On the other hand in type II circuits, the transcrip-
tion rates of the microRNA and target gene are differentially 
regulated by the up-stream regulator Fig. (1b). In reality ex-
ist more complex networks that these previously described. 
The c-myc/E2F1 and miR-20a circuit, is an example of type 
I circuit found in cancer Fig. (1c). The E2F1 transcription 
factor is activated by c-myc, which promotes cell cycle pro-
gression. Recently, it has been shown that c-myc activates 
the mir-17-92 cluster [66]. Specifically, miR-20a modulates 
the translation of E2F1 mRNA via binding in its 3'UTR. In 
addition, endogenous E2F1 directly bind to the promoter of 
mir-17-92 cluster activating its transcription. This example 
displays an auto-regulatory feed-back loop between E2F 
factors and miRNAs from the mir-17-92 cluster. In type II 
circuits, a miRNA regulates its targets coherently with tran-
scriptional control, thereby reinforcing transcriptional logic 
at the posttranscriptional level. Type II circuits may be 
prevalent, as genome-scale studies have shown that predicted 
target transcripts of several tissue-specific miRNAs tend to 
be expressed at a lower level in tissues where the miRNAs 
are expressed [67]. Type II circuit can be found in Droso-
phila eye development, where Yan is expressed in progenitor 
cells and miR-7 in photoreceptor cells [68].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(F: upstream factor; M: microRNA; T: target gene) 
Fig. (1). MicroRNA circuits in cancer. (a) Type I microRNA-
gene circuits. (b) Type II microRNA-gene circuits. (c) myc/E2F1/ 
miR-20a circuit in cancer.  
9. CONCLUDING REMARKS 
  The microRNA field although it is relatively new, there 
are more than 3000 publications related to microRNA func-
tions in many different organisms. However there are still 
many questions remaining unanswered. Do we know all the 
enzymes and proteins involved in microRNA production and 
processing? Except seed sequence complementarity, what 
are other factors contributing to miRNA-target gene recogni-
tion? How microRNAs are regulated in the transcriptional 
level?  
  On the other hand, we are just starting to uncover the 
huge potential of miRNAs as novel biomarkers and thera-
peutic targets for medicine. The small size of microRNAs 
and their ability to regulate cancer cell growth suggests their 
therapeutic potential. RNA interference gene therapies have 
been in use the last few years and most of the strategies used 
for delivering small interference RNA (siRNA) potentially 
can be used for microRNA delivery [69]. In the clinic, mi-
croRNAs inactivation could be accomplished through deliv-
ery of locked-nucleic-acid (LNA) antisense oligonucleotides 
against microRNAs [70]. These molecules are more stable 
and less toxic than other cancer treatments in order to target 
oncogenic microRNAs. The use of conjugated with choles-
terol antisense microRNAs seems an effective approach to 
inhibit microRNA activity according to murine studies [34]. 
On the other hand, overexpression of tumor suppressor mi-
croRNAs could be used to treat specific types of cancer. For 
example, let-7 family members are found frequently inacti-
vated in several cancer types. Thus let-7 overexpression us-
ing viral or liposomal delivery might be useful approaches 
for microRNA administration. In addition, let-7 overexpres-
sion has been shown to restore sensitivity to cytotoxic anti-
cancer therapies [71]. Of course there is need to develop 
novel microRNA delivery methods and treatments that will 
move microRNA therapies from the laboratory bench to the 
bedside. 
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